High Cardiac Risk of E-cigarettes: Russian Expert

Industry Insight by 2FIRSTS.ai

Dec.06.2023

High Cardiac Risk of E-cigarettes: Russian Expert

E-cigarette use increases cardiovascular disease risk, raises the chance of heart attacks and strokes by 56% and 33% respectively, warns Russian expert.

According to recent news from A42.RU, Dr. Aleksey Alekseyevichkov, head of cardiology at Kuzbass, Russia, and a candidate for medical science, has stated that e-cigarettes are extremely harmful, including a significant increase in the risk of cardiovascular diseases.

He emphasized that e-cigarettes are more likely to cause heart disease and stroke compared to regular cigarettes, with users facing a 56% increased risk of heart attacks and a one-third increased risk of stroke.

According to Alekseyevko, e-cigarette use can lead to the loss of elasticity in blood vessel walls, affecting oxygen supply and making users more prone to symptoms such as irregular heartbeat, chest pain, and rapid heart rate. Additionally, toxic substances produced by e-cigarettes can increase the risk of blood clotting and arterial hardening, with higher risk observed among women.

References:

[1] Главный кардиолог Кузбасса рассказал о связи курения вейпов и сердечного приступа

Also Read:

[1] Russian Duma Proposes Criminalizing Tobacco and Nicotine Advertising

[2] Russia Implements Label Requirement for E-Cigarettes and E-Liquids

[3] Russia Takes Action: Monitoring Enforcement of E-cigarette Sales Ban to Minors

#Europe #Open system e-cigarettes #Disposable e-cigarettes #Public health #Russia #E-cigarette #E-cigarettes and Tobacco

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer

Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.

Nov.26

U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned

Turning Point Brands (NYSE: TPB) released its financial results for the third quarter of 2025, reporting strong revenue and profit growth driven by surging Modern Oral (nicotine pouch) sales. The company announced plans to establish its first U.S.-based white pouch production line in 2026, marking a key step toward manufacturing localization.

Nov.06 by 2FIRSTS.ai

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways

2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.

Oct.13

SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores

According to an SKE release published on PR Newswire, the company is expanding its presence in the Korean market through convenience store and specialty retail channels. SKE has partnered with 7-Eleven Korea, placing its products in more than 5,700 stores nationwide, and is also working with OG9’s offline retail and B2B distribution network. On the product side, SKE is focusing on promoting the Crystal Bar TB1000 and Cloud Zero in Korea.